NCT04040361View on ClinicalTrials.gov

Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)

PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 30, 2019

Primary Completion Date

April 30, 2022

Study Completion Date

November 30, 2025

Conditions
Non-small Cell Lung Cancer Stage IBNon-small Cell Lung Cancer Stage IINon-small Cell Lung Cancer Stage ⅢA
Interventions
DRUG

Pembrolizumab

Pembrolizumab will be administered as a dose of 200mg as a 30-minutes IV infusion, Q3W

DRUG

Ramucirumab

Ramucirumab will be administered as a dose of 10mg/kg as a 60-minutes IV infusion, Q3W

PROCEDURE

Surgery

Surgery to be performed is lobectomy or more extensive lung resection and lymph node dissection

Trial Locations (2)

277-8577

RECRUITING

National Cancer Center Hospital East, Kashiwa

Unknown

RECRUITING

Tokyo Medical University Hospita, Shinjuku-Ku

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Eli Lilly and Company

INDUSTRY

lead

Masahiro Tsuboi

OTHER

NCT04040361 - Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY) | Biotech Hunter | Biotech Hunter